Zurich’s £7.7bn Beazley takeover bid goes public after board rebuff
19 January 2026
2 mins read

Zurich’s £7.7bn Beazley takeover bid goes public after board rebuff

London, 19 January 2026, 16:17 GMT

  • Zurich has raised its cash offer for Beazley to 1,280p a share, following the rejection of an earlier 1,230p bid
  • Beazley shares surged over 40% in London after the bid was announced publicly
  • Zurich has until Feb. 16 under UK takeover rules to either finalize the offer or pull out

Zurich Insurance Group revealed on Monday an upgraded all-cash bid for UK specialty insurer Beazley, offering 1,280 pence per share. The deal values Beazley at roughly £7.67 billion ($10.3 billion). Following the announcement, Beazley’s shares jumped over 40% in London. 1

The move spotlights a niche in insurance: specialty coverage, where insurers tackle more specific, complex risks and aim to price them precisely. At the heart of this sector is Lloyd’s of London, serving as a marketplace where syndicates underwrite everything from cyber attacks to shipping and property risks.

Zurich said acquiring Beazley would add Beazley’s Lloyd’s footprint to its specialty lines push and strengthen Zurich’s UK presence. It highlighted its newly established Global Specialty Unit, noting the merged company would generate roughly $15 billion in gross written premiums — premiums before reinsurance and deductions. 2

Zurich put forward a 1,230 pence per share cash offer on Jan. 4, but it was rejected, the company confirmed. Insurance Times described the bid as a significant move for the London-listed insurer. 3

Zurich’s updated 1,280p bid represents a 56% premium over Beazley’s closing price on Jan. 16 and a 27% premium to the median sell-side analyst target it referenced. Under UK takeover rules, Zurich must announce a firm offer or withdraw by 5 p.m. London time on Feb. 16. 4

Zurich plans to finance the deal with a mix of existing cash and new debt, topping up the rest through an equity placing—issuing fresh shares to investors. The company also confirmed the transaction will boost its 2027 financial targets. 5

Zurich CEO Mario Greco told the Financial Times this marks the group’s fifth attempt in about a year and that “it was time to go public” and hear from shareholders directly. Jefferies analyst Philip Kett described the bid as offering “fair value” but noted the roughly two-times price-to-book multiple—a comparison of the offer to the company’s net asset value—was “perhaps not as high as it could be.” The FT also reported Zurich is working with advisors Goldman Sachs, Lazard, and UBS. 6

Beazley, established in 1986, has made its mark in specialty underwriting, covering areas like cyber and fine art, according to The Times. Zurich, with a workforce exceeding 63,000, said the deal would form a larger specialty unit based in the UK. 7

Beazley has yet to respond to the recent approach. Zurich, however, described the move as a strategy to accelerate growth in specialty lines instead of expanding the platform organically.

The road ahead isn’t straightforward. Beazley’s board has yet to back the offer, and Zurich’s strategy depends partly on raising equity—something that gets tricky if markets falter or investors hesitate over the price. Regulators and Lloyd’s oversight loom as well. As Beazley’s shares hover near the offer price, the market begins to factor in the risk of the deal falling through—or the possibility of a better bid emerging.

The bid sparked renewed focus on other specialty firms listed in London, as investors looked for clues on sector valuations. A competing offer would swiftly challenge Zurich’s determination.

The next key date is mid-February. Should Zurich commit firmly by that point, attention will turn to Beazley’s board—whether they respond, the terms tied to any recommendation, and how Zurich’s funding plan stands up to close examination.

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs
Previous Story

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

Morgan Stanley Upgrade Lifts MDA Space as 2026 Space-Tech Funding Forecast Rises
Next Story

Morgan Stanley Upgrade Lifts MDA Space as 2026 Space-Tech Funding Forecast Rises

Go toTop